Core Viewpoint - The National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for the innovative EGFR x HER3 dual antibody ADC drug, iza-bren, developed by BaiLi Tianheng, aimed at treating recurrent or metastatic esophageal squamous cell carcinoma (ESCC) in patients who have failed previous PD-1/PD-L1 monoclonal antibody and platinum-based chemotherapy [1][2]. Group 1: Drug Development and Approval - The NDA acceptance is based on the interim analysis results from a Phase III clinical trial, which achieved both progression-free survival (PFS) and overall survival (OS) as primary endpoints [1]. - Iza-bren has been included in the priority review list by the CDE, indicating a potential commercialization in China within the year [1]. - This drug is expected to become the first standard treatment option for esophageal cancer in the ADC category [1]. Group 2: Market Need and Patient Impact - According to GLOBOCAN 2022, there are approximately 510,000 new esophageal cancer cases globally each year, with China accounting for about 224,000 new cases, representing 43.8% of the global total [2]. - In China, over 90% of esophageal cancer cases are esophageal squamous cell carcinoma, and there is a significant unmet clinical need for effective second-line treatment options after first-line immunotherapy [2]. - Iza-bren addresses this urgent need by providing a new treatment option specifically for patients who have failed previous therapies [2]. Group 3: Clinical Research and Recognition - Iza-bren is a core product in BaiLi Tianheng's innovative pipeline, with over 40 clinical trials ongoing in China and the U.S. across more than 10 tumor types [3]. - The drug has received multiple breakthrough therapy designations from both the CDE and the FDA, highlighting its competitive advantage and broad application prospects in the global oncology treatment landscape [3].